Widely used:Recently Viewed
Clear All$0.03
$0.00
(15.89%)
As on 23-Jun-2025 16:00EDT
Today’s Range
52 Week Range
Liquidity
Market cap
--
Revenue (TTM)
--
Net Profit (TTM)
--
ROE
--
ROCE
--
P/E Ratio
--
P/B Ratio
--
Industry P/E
--
EV/EBITDA
--
Div. Yield
--
Debt to Equity
--
Book Value
--
EPS
--
Face value
--
Shares outstanding
--
CFO
$-18.83 Mln
EBITDA
$-74.95 Mln
Net Profit
$-83.67 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Coeptis Therapeutics Holdings Inc (COEPW)
| 36.5 | -5.1 | 27.2 | 99.3 | -- | -- | -- |
|
BSE Sensex*
| 4.9 | 0.4 | 6.7 | 6.3 | 16.2 | 18.3 | 11.4 |
|
Company
|
2024
|
2023
|
|---|---|---|
|
Coeptis Therapeutics Holdings Inc (COEPW)
| -29.2 | -69.0 |
|
BSE Sensex
| 8.1 | 18.7 |
|
BSE Sensex
| 8.1 | 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple... myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania. Address: 105 Bradford Road, Wexford, PA, United States, 15090 Read more
Co-Founder, Chairman, CEO & Pres
Mr. David Mehalick
Co-Founder, Chairman, CEO & Pres
Mr. David Mehalick
Headquarters
Wexford, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Coeptis Therapeutics Holdings Inc (COEPW) is $0.03 (NASDAQ) as of 23-Jun-2025 16:00 EDT. Coeptis Therapeutics Holdings Inc (COEPW) has given a return of 99.33% in the last 1 years.
Coeptis Therapeutics Holdings Inc (COEPW) has a market capitalisation of -- as on 23-Jun-2025. As per Value Research classification, it is a company.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Coeptis Therapeutics Holdings Inc (COEPW) and enter the required number of quantities and click on buy to purchase the shares of Coeptis Therapeutics Holdings Inc (COEPW).
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania. Address: 105 Bradford Road, Wexford, PA, United States, 15090
The CEO & director of Mr. David Mehalick. is Coeptis Therapeutics Holdings Inc (COEPW), and CFO & Sr. VP is Mr. David Mehalick.
There is no promoter pledging in Coeptis Therapeutics Holdings Inc (COEPW).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Coeptis Therapeutics Holdings Inc (COEPW) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Coeptis Therapeutics Holdings Inc (COEPW) was $0 Mln.
